Sector
PharmaceuticalsOpen
₹2Prev. Close
₹0Turnover(Lac.)
₹0.04Day's High
₹2Day's Low
₹1.952 Week's High
₹052 Week's Low
₹0Book Value
₹1.16Face Value
₹10Mkt Cap (₹ Cr.)
4.29P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 22.59 | 22.59 | 22.59 | 22.59 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -19.81 | -19.24 | -18.83 | -18.66 |
Net Worth | 2.78 | 3.35 | 3.76 | 3.93 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Revenue | 42.81 | 38.66 | 32.85 | 27.45 |
yoy growth (%) | 10.73 | 17.67 | 19.68 | 16.79 |
Raw materials | -28.68 | -27.73 | -18.84 | -5.95 |
As % of sales | 66.98 | 71.73 | 57.35 | 21.68 |
Employee costs | -0.63 | -1.08 | -1.04 | -1 |
Y/e 31 Mar( In .Cr) | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Profit before tax | 4.1 | 3.67 | 1.85 | 1.22 |
Depreciation | -7.69 | -3.3 | -5.7 | -7.05 |
Tax paid | -0.65 | -0.34 | 0.22 | 0.06 |
Working capital | 12.24 | -30.5 | 2.3 | 2.33 |
Other operating items |
Y/e 31 Mar | Mar-2018 | Mar-2017 | Mar-2016 | Mar-2015 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.73 | 17.67 | 19.68 | 16.79 |
Op profit growth | 69.07 | -18.21 | -31.19 | 60.39 |
EBIT growth | 11.95 | 17.62 | -41.59 | 94.07 |
Net profit growth | 3.66 | 60.28 | 60.48 | 53.56 |
Particulars (Rupees in Crores.) | Mar-2023 | Mar-2022 |
---|---|---|
Gross Sales | 0.17 | 0.15 |
Excise Duty | 0 | 0 |
Net Sales | 0.17 | 0.15 |
Other Operating Income | 0 | 0 |
Other Income | 0 | 0 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,808.55 | 157.37 | 4,33,847.75 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,255.35 | 90.32 | 1,65,923.17 | 518 | 0.48 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,507.7 | 28.77 | 1,21,796.04 | 1,178.16 | 0.86 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.15 | 69.06 | 1,12,981.55 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,616.45 | 52.27 | 1,04,785.17 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
A N Singh
Director
Padma Singh
Director
Jeetainder Roy Gour
Company Secretary
Sada Naga Latha
Executive Director & CEO
Dattatreya Rao
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Celestial Biolabs Ltd
Summary
CELESTIAL LABS LIMITED was incorporated as a Private Limited Company on November 19, 1997 as Celestial Technologies Private Limited. Mr. Rajani Kanth Katragadda and Mr. Vijay Marur have promoted the company. The company was later converted into a Public Limited Company under the name Celestial Technologies Limited on December 6, 1999 and has been subsequently renamed as CELESTIAL LABS LIMITED effective from February 13, 2004. The present promoter of the company is Mr. Aditya Narayan Singh. The Original promoters sold their holding to the present promoter on 7.11.1998.The company has received ISO 9001-2000 certificate. The company has been providing customized enterprise solutions, bioinformatics services and also involved in development of biopharmaceuticals and industrial enzymes. The company is in contact with Centre for Cellular & Molecular Biology (CCMB) under the aegis of Council for Scientific and Industrial Research, Ministry of Science and Technology, Government of India and Indian Institute of Chemical Technology (IICT), premier chemical and Biological Institutions in Hyderabad to work on collaborative research projects to be funded by Department of Science and Technology New Delhi. The Company has offer both service and solutions like application management for legacy system, upgrade and maintenance system. Molecular informatics, data management, algorithm development, compliances and data curation, warehousing and visualization and custom built application are the
Read More
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice